Clinomics Signs Joint Business MOU with Japanese Drug Delivery Engineering Company Glytec

(From left) Baek Seohyun, CEO of Clinomics, Hiroaki Asai, CEO of Japan Glytec. / Photo by Clinomics

Clinomics announced on the 3rd that on the 31st of last month, it signed a memorandum of understanding (MOU) for joint business, including joint research and development with GlyTech, which is leading next-generation glycan engineering technology at Tohoku University in Japan, and exclusively providing glycan engineering technology to the domestic bio market.

GlyTech is a subsidiary of Otsuka Chemical under Otsuka Holdings, Japan's top chemical company, and is known as a leading company in next-generation glycan engineering technology with world-class glycan analysis and synthesis technologies.

Through this joint business MOU, Clinomics secured exclusive sales rights for glycan analysis requests from domestic pharmaceutical companies using GlyTech's technology, and plans to promote the attraction of domestic clinical partners for reagents under development by GlyTech.

One of the reagents currently being developed by GlyTech, "Somatostatin," is used as a growth hormone inhibitor to maintain hormonal balance in the body, primarily used as a treatment for the rare disease "Acromegaly." Although "Acromegaly" is a rare disease, the global treatment market forms about 2 trillion KRW, and "Somatostatin," as a reagent related to hormonal imbalance, is also expected to be developed in the future as a treatment for Alzheimer's disease, which is related to memory and brain function, as well as cancer and diabetes.

The company explained that one of the core technologies recognized as very important in modern bio-industry trends such as diagnostic/preventive medicine and new drug development is gene analysis technology and glycan engineering technology.

A Clinomics official stated, "Through this joint business MOU, Clinomics now possesses both of these technologies," adding, "By utilizing our gene analysis technology and Japan's GlyTech's glycan synthesis technology, we have secured the momentum to comprehensively research, develop, and commercialize health functional foods and reagents optimized for the Korean constitution."

This content was produced with the assistance of AI translation services.